Caris Life Sciences (CAI) investor relations material

Strategic direction and market trends

• Positioned to capitalize on expanding opportunities in precision medicine and oncology, leveraging a platform built since 2008.

• Achieved significant scale with over 200,000 annual profiles and a network of 6,100+ oncologists.

• Precision Oncology Alliance expanded to 100 sites, representing 4,000 oncologists and driving collaborative research.

• Patient-first philosophy drives technology and investment decisions, with deliberate expansion post-IPO.

• Large and growing total addressable market, with therapy selection penetration at 35% and emerging modalities like MRD just beginning.

Technology and product innovation

• Standardized on whole exome and transcriptome sequencing since 2019, offering the only FDA-approved assay of its kind.

• Launched Caris Assure for blood-based profiling and ChromoSeq for hematological cancers, expanding the product continuum.

• Developed MI Clarity, a digital pathology AI for breast cancer recurrence prediction, and GPSai for tissue of origin identification.

• AI and data science integral to platform, with 80+ PhDs mining one of the world’s largest genomic datasets.

• Early detection platform Achieve 1 demonstrated 60.3% stage 1/2 sensitivity, outperforming competitors.

Operational and financial performance

• Reported 79% year-over-year revenue growth in Q1, with molecular profiling revenues up 85%.

• Achieved four consecutive quarters of profitability and free cash flow positivity, enabling reinvestment and expansion.

• Average selling price for tissue profiling near $4,100 and for Caris Assure $2,421 in Q1.

• Expanded sales and pharma teams by 25–30% to drive further growth.

• Refinanced debt at lower rates, increasing strategic capital for new initiatives.